News | March 17, 2024
Sumitomo Pharma announces availability of ORGOVYX in Canada
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)